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Introduction. Hilar cholangiocarcinoma (HC) is a tumor that requires a multidisciplinary approach and treatment. 
The 3- and 5-year survival rates of HC patients treated with surgery and palliative methods were evaluated in the study.
Material and methods. The study covered 368 patients treated between 2000–2014. Of them, 137 patients were ca-
tegorized for surgery (RT group), and 231 for palliative treatment (PT group). The overall 3- and 5-year survival rates were 
determined by the log-rank test. The Cox hazard regression model revealed the relative prognostic factors. 
Results. The 3- and 5-year survival rates accounted for 38% and 21% after surgery, but 13% and 0 after palliative treatment 
(p < 0.0001). Radical tumor resection, negative lymph nodes, and early tumor T stage were the factors conducive to survival.
Conclusions. Surgery, if the radical tumor resection is possible, offers a chance for long-term survival. The effects of surgical 
treatment are of little consequence in the face of poor treatment outcomes of palliative patients, however.
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Introduction
Hilar cholangiocarcinoma (HC) is a tumor of the main lobar 
extrahepatic bile ducts, distal to segmental bile ducts and 
proximal to the cystic duct [1, 2]. Radical tumor resection that 
also covers the extrahepatic bile ducts and the unilateral part 
of the liver provides a chance to cure the disease, but selection 
of candidates remains challenging [5]. 
Studies on the results of HC treatment usually show the 
effects of surgery or the effects of palliative treatment in 
the particular groups of patients [3–6]. Few studies focus 
on an analysis of all patients admitted and treated at a mul-
tidisciplinary department of a single institution over a long 
period of time [7]. This prompted the presentation of own 
experience in the management of HC patients undergoing 
radical surgery and palliative care in the multidisciplinary 
HPB department of Medical University of Warsaw. The 3- and 
5-year cumulative overall survival rates and factors condu-
cive to the survival of the patients were the end-points of 
this study.
Material and methods
The study covered a cohort of 368 patients (F 178, M 190, 
median age 58.3, range 23–94, SD +/–13.9 years) with Klatski-
n’s tumors, who were transferred from public hospitals in the 
period of 2000–2014. Of them, 65% had already undergone 
bile duct stenting. Tumors were evaluated for radical surgery 
by using the T-stage classifications as assessed using CT, MRIch 
and USG imagings [8–11, 13]. The presence of adenocarcinoma 
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
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was confirmed in each case by the pathologist based on tissue 
biopsies and/or tissue material removed during surgery. The 
TNM clinical stage (UICC) was determined in patients who 
underwent surgery. 
Patients qualified for radical surgery
The group consisted of 137 (37.2%) patients (F 63, M 74, median 
age 57.3 years, (range 23–78, SD +/–12.2). 87 patients (F 37, M 
50, median age 57.3 years) were already prosthetized before 
the transfer. The tumor was of stage Bismuth-Corlette II, IIIA, 
and IIIB in 6, 81 and 50 patients, respectively. Tumor clinical 
stage of T1 was determined for 29 patients and T2 for 108. The 
extended right hemihepatectomy included the right liver lobe, 
the inferior part of segment IV, the hilar plate, and the entire 
caudate lobe. The extended left hemihepatectomy included 
the left liver lobe, the right paramedian sector of the hilar plate, 
and most of the caudate lobe. Six tumors of the Bismuth II type 
were excised locally. Lymph nodes of the celiac axis, common 
hepatic artery, and all lymphatic structures in the hepato-
duodenal ligament were coupled with complete resection 
of the extrahepatic bile duct in all of the patients. A frozen-
-section analysis of the margins was used to guide resection. 
The biliary tract continuity was restored by the anastomosis 
of the remaining hepatic duct to the Roux-Y jejunal loop. The 
postoperative course was uncomplicated in 78 patients (57%). 
14 patients (10.2%) died due to postoperative complications. 
The result of R0, R1, and R2 tumor resection was obtained in 100 
(73%), 24 (17.5%), and 13 (9.5%) of the patients, respectively. 
The extent of carcinoma infiltration within the removed tissues 
was described in details by the pathologist in every patient. The 
TNM clinical stage was determined as T1N0M0 in 29 patients, 
T2N0M0 in 58 patients, and T3N1M0 in 50 patients. Adjuvant 
chemotherapy was applied only to 37 patients undergoing 
R1/R2 tumor resection. The details are presented in table I. 
Patients having tumors clearly unresectable 
(Palliative A) 
The group consisted of 210 patients (57.3%, F 101, M 109, 
median age 59.9, range 26–94, SD +/–11.0 years). Of them, 
66% were already prosthetized before the transfer. The tumor 
was of stage Bismuth-Corlette II, IIIB and IV in 5, 25, and 180 pa-
tients, respectively. Radiologic tests indicated clearly the tumor 
unresectability (clinical T3 stage). No distant metastases were 
found in any of the patients, however. Infiltration of the bile 
duct by cholangiocarcinoma was confirmed by the pathologist 
in specimens obtained by biopsy or biliary brushing during 
ERCP. Clinical advances of the tumor were not possible to be 
calculated (TxNxM0).
Patients having unresectable tumors, as found 
during laparotomy (Palliative B)
In 21 patients (5.7%, F 14, M 7, median age 59.2, range 48–76, 
SD +/–14.2 years) imaging studies indicated the possibility of 
radical operation. Tumor was of stage Bismuth-Corlette IIIA in 
8 patients, and IIIB in 13, and the clinical stage T2 was deter-
mined by radiologic tests. The operative exploration allowed 
to recognize excessive tumor involvement (T3 stage) and its 
unresectability. The reason for withdrawing them from radical 
surgery was tumor involvement of the main trunk of the portal 
vein in 14 cases, involvement of the common hepatic artery 
in 4, and the tumor’s extensive spread to the contralateral 
duct in 7 patients. Operations ended after collection of tissue 
specimens. All patients were treated by endoscopic stenting 
over the postoperative period. Postoperative complications 
were frequent. Pathologic diagnosis was obtained by examina-
tion of the specimens taken during the explorative operation. 
Perineural invasion and lymph nodes invasion of the tumor 
were present in all patients. No distant metastases were found. 
The TNM stage of T4N1M0 was determined in all patients.
Palliative care modalities
The group of palliative patients consisted of 231 patients in 
total (63%, F 115, M 116, median age 58.9, range 26–94, SD 
+/–13.6 years). Endoscopic stenting of the bile duct tree was 
applied to all 231 patients. Depending on individual indica-
tions, plastic stents or different types of SEMSs prosthesis were 
inserted to provide effective bile drainage. The procedure was 
effective in 199 patients (86.1% out of 231 in this group), and 
uncomplicated in 145 (62.7%). 13 patients (5.6 %) died due 
to a failure in the procedure or serious biliary complications. 
In the follow-up period, plastic stents were usually changed 
every 2–4 months. Metal SEMS prostheses were targeted for 
permanent decompression of the biliary tree, however, more 
than 50% had intermittent cholangitis along with the treat-
ment. Early complications also included infection, bleeding, 
pancreatitis, and often occlusion caused by sludge in both 
types  of stents. Dislodgment happened in 14% and in 5% 
of the fully and partially covered SEMS prostheses. 76 of the 
patients (33%) received chemotherapy by using gemcitabine 
and platinum-based regimens, according to the oncologist’s 
order. The details are presented in table II.
Statistical analysis 
 Data were summarized with follow-up to December 31, 2019. 
Cumulative overall patient survival rates at 3 and 5 years were 
determined as percent of patients and calculated by the Ka-
plan–Meier method using the log-rank test with adjustment for 
the type of treatment. The Chi-square test was used to analyze 
categorical data. The Cox proportional hazard regression model 
was used to assess the relative prognostic factors influence on 
patient survival. Values of p < 0.05 were considered significant. 
Results
14 out of 137 patients from the RT group (10.2%), and 13 out 
of 231 patients from the PT group (5.6%), died during treat-
ment due to serious complications (p > 0.71). The median 
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Table I. Demographic data, tumor features, procedures used and complications in patients treated by surgery
Patients treated by surgery
Number of patients: 137 (37.2%); F 63, M 74, median age 57.3 (range 23–78, SD +/–12.2)
Overall results of surgery: R0 – 100 (73%), R1 – 24 (17.5%), R2 –13 (9.5%)
Detail description of variables Numberof patients Female Male
endoscopic prosthesis procedure prior to referral 
yes 87 (63%) 37 50
no 50 26 24
 Right extended hemihepatectomy for Bismuth–Corlette type IIIA



















Left extended hemihepatectomy for Bismuth–Corlette type IIIB



















Local tumor resection for Bismuth–Corlette type II  
effects of surgery T-stage TNM class. No. of pts. 6 3 3
R0 T1 T1N0M0 6 6 3 3
Results of pathologic examination
lymph nodes infiltration
yes 50 19 31
no 87 44 43
liver parenchyma infiltration
yes 64 31 33
no 73 32 42
perineural invasion
yes 33 13 20
no 104 50 54
Postoperative course and complications (Clavien–Dindo scale)
unomplicated 78 (57%) 40 38
grade I 12 2 10
grade II 15 9 6
grade III 5 0 5
grade IV 13 5 8
grade V (death) 14 (10.2%) 7 7
Adjuvant chemotherapy ( all R1 and R2 patients) 37 (27.7%) 15 22
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was 20.5% and 0, respectively (log-rank test – 3.15, p < 0.002). 
No significant differences in the 3- and 5-year survival rates 
were found between patients undergoing R1 resection (su-
rvival rates accounting for 21% and 0%) and R2 resection 
(survival rates accounting for 11.5% and 0), (log-rank test – 0.60, 
p > 0.54; in between patients undergoing R1/R2 resection and 
those treated with palliative methods (log-rank test – 0.65, 
p > 0.58); in between the palliative patients who received 
adjuvant chemotherapy and those who did not receive 
it (log-rank – 0.87, p > 0.28) (fig. 1). 
The effect of T-stage
Patients categorized by T-stage classification were eligible for 
tumor resection while being in the T1 or T2 tumor stage. Re-
section R0 was achieved in 35 patients with T1 and 65 patients 
with T2 tumors, while R1 and R2 resection was achieved in 24 
survival time for the 368 patients participating in the study 
was 15.3 months, whereas the cumulative survival rates of 
3- and 5-years were 27% and 11%, respectively. The median 
survival time of patients treated by surgery was 19.5 months 
(including patients with R0, R1, R2 resections of 24, 17, and 14 
months, respectively), and for patients treated by palliative 
methods it was 13 months (p < 0.001). Statistical values are 
shown in table III.
The effect of R0 resection 
The 3- and 5-year cumulative survival rates in the 137 patients 
treated by surgery were 38% and 21%, whereas in the 231 
patients treated with palliative methods it was 13% and 0, 
respectively (log-rank test – 5.01, p < 0.0001). On the other 
hand, in the 100 patients undergoing R0 resection it was 50% 
and 30%, but in the 37 patients undergoing R1/R2 resection it 
Table II. Demographic data, tumor features, procedures used and complications in patients treated by palliative methods
Patients treated by palliative methods
No. of patients: 231 (63%); F 115, M 116, median age 59.9 (range 26–94, SD+/–11.6) years
Detail description of variables No. of patients Female Male
endoscopic prosthesis procedure prior to referral
yes 140 (66%) 77 63
no 70 24 46
Palliative A: unequivocally not for resection 






Bismuth type III/B 25 15 10
Bismuth type IV 180 85 95
Palliative B: excessive tumor development, “unnecessary laparotomies” 






Bismuth type IIIB 13 11 2
Pathologic examination of tissue samples
lymph nodes infiltration yes 21 14 7
liver parenchyma infiltration not tested not tested
perineural invasion yes 21 14 7
Palliative A & B: procedures used
metal stent replacement instead of existing plastic stents 114 (49%) 27 87
new stenting procedure due to jaundice by plastic / metal stents 96 69 27
explorative laparotomy; plastic or metal stents introduced after 21 14 7
Palliative A & B: complications after procedures (Clavien–Dindo scale)
uncomplicated 145 (69%) 80 65
grade I 24 3 21
grade II 17 10 7
grade III 25 8 17
grade IV 19 11 8
grade V (death) 13 (5.6%) 5 8
palliative A & B: adjuvant chemotherapy 76 (33%) 39 37
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and 13 patients, all with T2 tumors. The median survival time 
of patients with T1 tumors was 29.1 months and of patients 
with T2 tumors – 15.5 months. On the other hand, all patients 
with T3 tumors were suitable only for palliative treatment, with 
a median survival time of 13 months. The median survival of all 
368 patients that were categorized by T-stage was 14.7 months. 
Further analysis by multiple comparisons showed that the 
survival time of patients with stage T1 tumors was significantly 
longer than those with stage T2 (p < 0.015), and T3 (p < 0.002). 
No significant difference was found in the survival time of 
patients with T2 and T3 stage tumors (p < 1.0), (tab. IV). The 
T-stage of a tumor corresponded clearly to its local growth 
and spread, as was confirmed by the pathologist in post-
-operative specimens that had been removed. Only patients 
determined as T1-stage possessed tumors in the early stage 
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Value ‘z’ for multiple comparisons;
independent variable (grouping):
treatment modality
Kruskal-Wallis test:  




P value for multiple comparisons; 
independent variable (grouping):  
treatment modality
Kruskal-Wallis test:  
H (2, N = 368) – 31.27 p < 0.0001
R0 R1 + R2 PT R0 R1 + R2 PT
R0 2.81 R0 0.014 0.0001
R1 + R2 2.81 R1 + R2 0.014 1.00
PT 5.56 0.85 PT 0.0001 1.00
Figure 1. Kaplan–Meier survival estimate of patients with curatively intent surgeries and with patients treated with palliative methods. A. Survival 
time differed significantly between R0 and R1/R2 resection; B. No significant difference in survival time was found between resection R1 and R2; C.No 
significant difference in survival time was found between resection R1/R2 and palliative treatment; D. Survival time differed significantly between R0 
resection and palliative treatment  
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were more advanced (T2N0 and T3N1). Their survival time was 
shorter, and unfortunately, it did not differ significantly from the 
survival of palliative patients treated. The results indicate the 
dependence of long-term outcomes from the clinical T-stage 
of tumor development, but also lymph node involvement in 
the cancer mass. 
Prognostic factors
The analysis revealed that R0 tumor resection, the negative 
lymph nodes, and the tumor at T1-stage, are factors favorable 
for patients’ survival (p < 0.001 and 0 < 0.02). Consequently, the 
less advanced the tumor is, the easier it is to achieve radical 
resection and the better the long-term result (tab. V). The 
differences in the cumulative survival rates that would arise 
from the patients’ sex, age, and postoperative complications or 
differences in the operative or endoscopic treatment modality 
were found to be statistically not significant. 
Discussion 
The study demonstrated that R0 tumor resection offers a chan-
ce at long-term survival, however the procedure can be applied 
in only circa 30% of cases. In such patients, the 3- and 5-year 
cumulative survival rates were 50% and 30%, respectively, with 
a perioperative mortality of 10.2%. Although the resection 
was challenging in numerous cases, the postoperative com-
plications were not frequent, and the postoperative mortality 
accounted for 10.2 %, since only 14 patients died. The results 
corresponded to experience presented i.e. by van Gulik et al., 
Zhang et al., Baton, et al. and some others [19–24]. 
The study showed that the T-staging system served as 
a good indicator for postoperative prognosis. The oncologic 
radicalism has been achieved following the principles of liver 
surgery that are generally known and accepted [2, 7, 11–16, 
21, 22]. A particular strength of the present study was that the 
diagnosis of hilum carcinoma was confirmed in all patients by 
positive histology or cytology. Therefore, the clinical stage of 
the patients could be classified according to UICC/AJCC system 
[7, 16, 18]. The pathologic examination of the operative spe-
cimens showed that all T1-stage patients should be classified 
as T1N0M0, whereas T2-stage patients as at least T2N0M0, but 
also as T2N1M0. This indicated a close correlation between 
the T-staging system, the multifactorial pTNM staging and the 
clinical stage of tumor development, which is obvious and 
confirmed by years of experience [13–17, 23–25]. Therefore, 
the median survival time of patients with T1 tumors was signi-
ficantly longer than of patients with T2 tumors, regardless that 
the resection was R0 in each case (p < 0.015). No significant 
difference was found, however, in the median survival time of 
patients with T2 tumors undergoing palliative resection and 
the T3 tumors, treated with palliative methods (p > 1.0). In fact, 
all patients who underwent tumor resection, limited to the sta-
te of R1 and R2, were classified as T3N1M0 by the pathologist. 
The above data has suggested that patients without lymph 
node involvement have a better survival chance. Actually, the 
negative lymph nodes were found as one of the factors con-
ductive to the survival of the patient in the multivariate analysis 
by using the Cox regression model in this study. The literature 
provides conflicting results regarding the association of lymph 
node status on survival, with some authors showing a clear 
effect [14, 22] and some showing none [7, 26]. Nonetheless, 
our results indicate the dependence of long-term outcomes 
from the clinical T-stage of tumor development, but also the 
lymph node involvement in the cancer mass. Consequently, 
the less advanced the tumor, the easier it is to achieve radical 
resection and the better the long-term outcome [4, 7, 13–17].
The effectiveness of the preoperative assessment has pro-
ven insufficient in over 15% of patients. In fact, they had an 
advanced cancer, which was confirmed during explorative 




Value ‘z’ for multiple comparisons;  
independent variable (grouping):
T-staging system
Kruskal-Wallis test:  
H (3, N = 368) – 18.33 p = 0.0004
Dependent 
variable
    Survival time
P value for multiple comparisons;  
independent variable (grouping):
T-staging system
Kruskal-Wallis test:  
H (3, N = 368) – 18.33 p = 0.0004
T1-stage T2-stage  T3-satge T1-stage T2-stage T3-stage
T1-stage 3.02 3.54 T1-stage 0.015 0.002
T2-stage 3.02 0.55 T2-stage 0.015 1.00
T3-stage 3.54 0.55 T3-stage 0.002 1.00
Table V. Results of multivariate analysis using the Cox regression model for factors conducive to patient survival
Parameter Chi-square Pr > ChiSq Hazard ratio
tumor resection R0 vs. R1/R2 14.79 <0.001 2.29
lymph nodes negative vs. involved 21.08 <0.001 2.27
tumor T1-stage vs. T2/T3 5.21 <0.02 1.55
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laparotomy or the surgery had to be limited to the stage R1/
R2 (all T4N1M0). The problem is generally known as “unneces-
sary laparotomies”, and is mentioned as one of the causes of 
poor treatment results in HC patients. However, the study by 
Jarnagin et al. [7], and Zhang et al. [20] reveal longer survival 
rates after palliative tumor resection. Also, Baton et al. [21] 
found that R1 hepatic resection with no other risk factors can 
offer better long-term survival. On the other hand, in a study by 
Seyama et al. [22], no difference in survival was seen between 
R0 resection with a margin <5 mm and R1 resection. Indeed, 
the 3- and 5-year cumulative survival rates were longer in R1 
than R2 of patients, but, the difference was statistically irrele-
vant (log-rank test – 0.6, p > 0.54). Moreover, survival rates of 
patients after a palliative R1/R2 resection and patients treated 
with endoscopic methods were statistically also irrelevant (log-
-rank test – 0.65, p > 0.58). It was exactly one month longer 
than in patients treated with endoscopic palliative modalities. 
Stenting procedures were successful in 86.1% of unresectable 
patients. SEMS prostheses were generally preferred to plastic 
stents, however, in most advanced cases, plastic stents were 
considered sufficient. Complications were not numerous and 
hospital stay mortality concerned 5.6% of patients. Others 
estimate the success rate at 55% to 90% of the adequate endo-
scopic drainage for hilar tumors, also indicating a higher risk of 
cholangitis in such patients [27–29]. Surprisingly, and contrary 
to studies demonstrating the clear advantage of gemcitabine/
cisplatin-based chemotherapy, we found no significant diffe-
rences in the survival of patients who were treated this way 
(log-rank – 0.87, p > 0.28) [24–26]. The results quoted above 
correspond to some other reports [7, 11, 18, 19, 30]. 
The positive effects of surgical treatment are obscured 
by the vast majority of patients presented with advanced 
locoregional disease. This is clearly demonstrated by the poor 
overall survival of the whole population that is accounted in 
months, despite the efforts and significant achievements in 
the treatment of non surgical patients [1, 4, 7, 8, 15, 22, 23]. 
The analysis showed that 231 patients were in the T3-stage 
of the tumor, denoting unilateral or contralateral portal vein 
involvement and homolateral or contralateral hepatic atrophy, 
that corresponded to clinical stage T4NxM0, according to 
UICC/AJCC classification [7, 16, 24–26]. The main goals for the 
palliation of patients with advanced hilar cholangiocarcinoma 
are decompression of the biliary system and control of tumor 
growth by chemo- radiotherapy [5, 11, 27, 28]. However, adju-
vant treatment (radiotherapy, chemotherapy or a combination 
of both procedures) for locally advanced tumors, and especially 
for tumors with distant metastases, seems not to influence 
the oncological outcome in terms of disease-free survival and 
overall survival [7, 14, 22, 24]. Our modest results achieved in 
patients with palliative methods seem to confirm this experien-
ce. This is one of the most challenging malignancies of the liver 
and the biliary system. The overall survival of patients suffering 
from hilar chiolangiocarcinoma is poor, in spite of progress in 
modern diagnostics and methods of treatment [7, 8, 15, 16, 
18, 22]. The biological behavior of the tumor and its strategic 
location are the principal reasons for this state of affairs. 
In Polish literature, there are no analyses of multicentre 
clinical studies concerning the diagnosis and treatment of 
the Klatskin tumor. Reports on the outcomes after radical 
and palliative surgical treatment are particularly lacking. Pe-
ripheral hepatico-jejunostomy is proposed by some authors 
as an alternative palliative surgical method of treatment in 
advanced cases [31, 32]. Most seem to rely on the implantation 
of plastic and metal stents, which in practice, was primarily 
used for palliation of the patients discussed in our study [33, 
34]. Overall, the treatment results are poor; 5-year survival is 
defined as about 1% in all treated for CCA patients and up to 
20%, if it is possible to treat patients by radical surgery [31–33]. 
The effectiveness of chemotherapy in the treatment of hilar 
carcinoma is low, however, it is proposed as an adjuvant or 
palliative in selected patients. Constant control observations, 
biochemical and imaging tests are recommended, depending 
on the clinical course [35, 36]. 
Polish experiences differ somewhat from the trends pre-
sented in many contemporary reports. Tumor resection is still 
the only potentially curative option for Klatskin tumor patients, 
although only a small percentage of patients are eligible for 
surgery. The side of the liver resection does not impact the 
perioperative and long term outcomes in patients undergoing 
curative-intent resection. A surgical strategy should be planned 
based on the possibility of achieving R0 resection with the con-
firmed negative margin of tissue by histopathologic test. The 
5-year overall survival rates after radical tumor resection varied 
from 20% to even 40% [37, 38]. Radical operative treatment is 
proposed even for locally advanced tumor stages. The criteria 
for resectability include absence of liver metastases, absence of 
carcinomatosis, and absence of vascular invasion. Local tumor 
advancement plays a minor role in these considerations [39]. 
A critical assessment of the patient’s preoperative imaging is 
necessary to determine tumor resectability. The advantage 
of T-stage over Bismuth-Corlette tumor classification for such 
purposes is stressed in many studies [40, 41]. The percentage 
recurrence is high. The problem is that we still lack accurate 
noninvasive biomarkers for the diagnosis and to estimate the 
prognosis while evaluating patients populations. So, definitive 
resection, combined with adjuvant therapy to reduce the risk 
of recurrence should be the standard approach for selected 
patients. Chemotherapy medications that are used are  flu-
orouracil, gemcitabine, and cisplatin [39–42]. If surgery is not 
possible, in unresectable Klatskin tumors, the patients should 
be treated by radiotherapy and/or chemotherapy. Low-dose 
chemotherapy can make the tissue more sensitive to radiation, 
however, radiation therapy can be used with or without low-
-dose chemotherapy. Gemcitabine combined with cisplatin 
therapy has been recognized recently as a standard treatment 
for unresectable Klatskin tumors [39, 40]. In Germany, radiation 
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therapy for Klatskin tumor is used after partial tumor resection. 
It is also used as the main treatment method for advanced 
stages of cancer [43]. Decompression of the biliary tract plays 
an important role in the treatment process. Stents should 
be placed by percutaneous transhepatic USG or CT guided 
procedures instead of standard ERCP procedure to avoid po-
ssible intrahepatic infection. However, chemotherapy is not 
recommended as the neoadjuvant treatment since it can delay 
more effective therapy possibly even by months [39, 40, 42]. 
The results presented in the paper correspond, to a large 
extent, to results presented in recent professional literature. 
This is because the approach to the treatment has correspon-
ded with changing and constantly modernizing treatment me-
thods in the leading world HPB Centers. The large sample size 
and long study period are certainly strengths of this study, but 
the analysis may exhibit some bias characteristic for studies car-
ried out over a long time period on a large sample of patients 
with a very specific type of disease. Thus, localization and the 
extent of the malignancy could be sources of bias, especially 
in patients with diseases in their advanced stage, since they 
were diagnosed and categorized mostly by evaluation and 
interpretation of radiologic images. The stage of classification 
was just presumed in some patients with advanced tumors, 
and this can be biased, since it was based on the results of 
cytology and radiologic images. Moreover, the causal-effect 
relationship between procedures and a patient’s long-term 
outcome may have given rise to a small amount of bias in the 
interpretation of the results. However, as regarding treatment 
modalities, all procedures were performed by the same high-
ly experienced specialists, according to the same operative 
procedures. Subsequently, any variations in performance of 
the procedure caused by the individual nature of a particular 
specialist, were too small to generate significant differences. 
Therefore, we believe that the study results can be generalized 
due to the considerable large number of patients included in 
the study, followed up on for a relatively long time, but with 
proper caution exercised due to its limitations and bias. 
Conclusions
Surgery, if radical tumor resection is possible, offers some chan-
ce for long-term survival. The effects of surgical treatment are 
of little consequence in the face of poor treatment outcomes 
of palliative patients, however. Unfortunately, the majority of 
hilar tumors are diagnosed in their advanced loco-regional 
stages. This state of affairs results from the biologic behavior 
of the tumor and its location. 
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